Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Let The Games Begin, Says COVID-19 Vaccine Quad Alliance

US Supply Constraints To Be Addressed?

Executive Summary

A COVID-19 vaccine alliance between US, Japan, India and Australia announced funding for Johnson & Johnson’s vaccine made by Biological E. Will the arrangement be extended to other vaccines and will the alliance push US to address materials export concerns, recently raised by Serum Institute?

You may also be interested in...



Biological E's COVID-19 Vaccine Launched, MD Says India Supplies To WHO Not Under Threat

Despite Indian companies not being able to honor COVID-19 vaccine export commitments, Biological E’s MD believes mitigating circumstances mean relations with the agency won’t be damaged. Meanwhile, Corbevax is being used in India's immunization program and a tech transfer for Johnson & Johnson’s COVID-19 vaccine is going ahead.

Eight COVID-19 Vaccines Approved In India In 2021, mRNA Addition Awaited

While an mRNA vaccine is still missing, 2021 saw Indian companies strike alliances, battle legal action and gain funding while the regulator played a crucial enabling role in the run up to the approval of eight COVID-19 vaccines from zero in 2020.

UK Travel Rule Sparks Row As India Seeks To Resume COVID-19 Vaccine Diplomacy

As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel